Stay updated on Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0, replacing the previous version v2.9.7.
    Difference
    0.2%
    Check dated 2024-07-23T14:52:21.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T06:39:14.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the version of the content on the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T14:18:35.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T10:23:52.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content version.
    Difference
    0.1%
    Check dated 2024-06-26T09:27:51.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Show more Revision: v2.9.0' has been updated to 'Show less Show less MedlinePlus related topics: Vaccines Drug Information available for: Nivolumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : ISA101 + Nivolumab HPV-16 vaccination (ISA 101) administered subcutaneously at 100 mcg for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1. Nivolumab administered intravenously at 3 mg/kg every 2 weeks beginning on day 8 after the first vaccine dose. There are 3 weeks in Cycle 1 and 2 weeks in Cycles 2 and beyond. Biological : ISA 101 100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1. Drug : Nivolumab 3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.' This change represents an update in the study details and treatment information for the clinical trial.
    Difference
    29%
    Check dated 2024-06-25T08:44:00.000Z thumbnail image

Stay in the know with updates to Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page.